Search

Displaying results 2881 - 2890 of 6198 in total
  1. Drug

    Florquinitau (18F)

    go.drugbank.com/drugs/DB19215
    ApprovedInvestigational

    [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease

  2. Drug

    Huperzine A

    go.drugbank.com/drugs/DB04864
    ApprovedInvestigationalWithdrawn

    It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.

  3. Drug

    Lanthanum carbonate

    go.drugbank.com/drugs/DB06792
    Approved

    Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. … It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733]

  4. Drug

    ZK-93423

    go.drugbank.com/drugs/DB17063
    Experimental

    ZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.[A253172]

  5. Drug

    Navafenterol

    go.drugbank.com/drugs/DB19195
    Investigational

    Navafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).

  6. Drug

    Amfecloral

    go.drugbank.com/drugs/DB08924
    Experimental

    For a short period of time, it was available under the brand Acutran and indicated as an appetite suppressant, but this product no longer exists. … This would produce an effect similar to the amphetamine/barbiturate combinations previously used in psychiatric medications.

  7. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects … adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy.

  8. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.

  9. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    Targeting IL-6 function can be achieved directly, or through interrupting the IL-6 receptor or gp130 receptor axes. … Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.

  10. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.